Search Immortality Topics:

Page 4«..3456..1020..»

Category Archives: Nano Medicine

Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market – BioSpace

Medical Physics Market: Overview

Medical physics has transformed practice of diagnostic and therapeutic medicine, which relates to the use of radiation in medicine. The role of medical physicists in ensuring quality radiation therapy, improving the performance of quality medical imaging is a key factor underpinning the evolution of the medical physics market.

Research in medical physics has focused on assessing the potentially harmful effects of radiation on patients, clinicians, and healthcare staff. Strides that diagnostic and therapeutic medicine has made over the past few years have shaped the growth trajectory of the overall medical physics market. The expanding role of radiology, radiotherapy, and nuclear medicine in diagnostics and therapeutics is a case in point.

Over the years, physicists have been increasingly leaning on discovering processes, procedures, and technologies, that will expand the scope and relevance of healthcare applications. These efforts reinforce the growing outlook of the medical physics market.

Request Brochure of Report -

Medical Physics Market: Competitive Analysis and Key Developments

In recent years, medical physicists are being exhorted to improve their contribution to healthcare systems world over. A number of frameworks supporting related strategies is key to offering momentum in this direction. The American Association of Physicists in Medicine (AAPM ) in 2018 devised such a framework Medical Physics 3.0 (MP 3.0) after two years of relentless deliberations to this end. This will help greatly reinvigorate the role of medical physics in patient care in general, expanding the horizon of the market.

The association has urged physicists to securitize their role in medical area, and eventually gain a comprehensive understanding of patient care. Such initiatives are helpful in boosting the prospects of the medical physics market. Experts believe that Medical Physics 3.0 (MP3.0) is likely to set the pace for sustainable excellence in medical physics, my maximizing the contribution of physicists to improvement of human health.

Over the past few years, the medical physics market has been replete with mergers and acquisitions among the healthcare system manufacturers and healthcare providers. This has helped in boosting the adoption of cutting-edge diagnostic imaging in the medical physics market.

Request for Analysis of COVID-19 Impact on Medical Physics Market -

Medical Physics Market: Key Trends

Medical physicists have been instrumental in improving the clinical efficacy and safety of wide spectrum of diagnostic and therapeutic modality. These include mammography systems, X-ray systems, computed tomography, magnetic resonance imaging, SPECT, and PET. Key end users include hospitals, academic and research institutes, ambulatory surgery centers, and diagnostic imaging centers.

The need for reducing radiation toxicity in tomotherapy and intensity modulation radiotherapy (IMRT) is boosting the medical physics market. Medical physics is a mix of scientists and healthcare and medical professional. Thus, their role in transforming human and animal health has expanded the vistas in medical physics market.

Request for Custom Research -

In coming years, future slew of investments in the medical physics market include orthopedics, ophthalmology, medical photonics, surgery, radiogenomics, nano?medicine, dentistry, vascular medicine, and neuro?science.

Medical Physics Market: Regional Analysis

On the regional front, North America and Europe have been vastly attractive medical physics markets. These regional markets have seen the increasing trend of outsourcing of medical physics. In recent years, the role of numerous regional associations, notably in the U.S., in expanding the role of medical physicists in human health has cemented the revenue potential of the global medical physics market. Strides being made by nuclear medicine have spurred revenues in the North America medical physics market.

Pre Book Medical Physics Market Report at

The growing incidence of chronic diseases in developing regions such as Asia Pacific and Latin America is opening promising investment scope in these, making them fast emerging markets.

Browse More Trending by Transparency Market Research:

Injectable Benzodiazepine Market:

Oncology Small Molecule Drugs Market:

Protein A Resin Market:

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

ContactTransparency Market Research,90 State Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA - Canada Toll Free: 866-552-3453Website:

Go here to see the original:
Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market - BioSpace

Posted in Nano Medicine | Comments Off on Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market – BioSpace

The advent of biomimetic apatites in today’s and tomorrow’s medicine – Open Access Government

Open Access Government spoke to Prof Christophe Drouet (CNRS Senior Scientist) an international specialist in bio-inspired apatites to learn more about this most absorbing field of research, dealing with regenerative and nanomedicine

Nature has always been a great source of inspiration for humans This is especially true considering biomineralisations as in bones and teeth. By appropriately tuning their composition and conditions of formation in vivo, Nature has designed its own biomaterials, capable of cumulating at once with mechanical strength and bioactivity. Such biominerals are essentially composed of calcium phosphates with an apatite structure, and we have learned over time to master the preparation and processing of synthetic analogues, so-called biomimetic apatites.

This is one focus of our research group in Toulouse. By mimicking crystals naturally present in our bones, these intrinsically biocompatible compounds are particularly well suited to the design of biomaterials for use in vivo: whether in view of bone regeneration or beyond!

In all cases, it is also possible to convey additional functionalities such as anticancer or antimicrobial by exploiting the exceptional surface reactivity of these compounds.

Biomimetic apatites are prepared by soft chemistry, thus avoiding the use of high temperatures to preserve their reactivity and intrinsic features. Indeed, as in natural bone mineral, biomimetic apatite crystals are covered by a hydrated non-apatitic ionic layer which confers to these compounds an exceptionally high surface reactivity, which can be exploited because of biomedical applications. (1) It is then possible provided that the adequate experimental conditions are used to graft on their surface a large variety of bioactive molecules/drugs to set up medical devices.

We have, for instance, shown the possibility to associate antibacterial enzymes, antibiotics, anticancer drugs, hemostatic agents, cell-targeting moieties, anti-osteoporotic drugs, vitamins, and so on to design la carte bioactive compounds. Also, the possibility to modulate their ionic composition allows doping them with bioactive ions which may also play a role in the control of microbial colonisation, inflammation, etc.

Biomimetic apatites are increasingly considered by researchers and clinicians for the design of innovative implantable biomaterials in orthopaedics and dentistry. Using such bio-inspired apatites may indeed ensure not only a high biocompatibility, but also a tailorable resorption rate, which may be modulated via their chemical composition and processing approach. Plus, as mentioned above, several strategies can be developed to confer additional therapeutic functionalities.

Starting in 2004, our group showed for the first time that it was possible to consolidate biomimetic apatite powders into actual 3D scaffolds via cold sintering by a technique called Spark Plasma Sintering (SPS). (2) This opened the way to low-temperature consolidation approaches to preserve the characteristics and performances of such bio-inspired apatites. This low-temperature consolidation is possible by the presence of water molecules on the crystal surface, allowing significant ion mobility.

Lately, this possibility was also extended to amorphous calcium phosphates, often considered as precursors of bone formation in vivo, while preserving again the appealing physicochemical properties of these metastable compounds. (3) We also showed, more recently, that it was possible to coat existing implants (ceramics, metals) such as hip, knee or dental implants with biomimetic apatites so as to significantly increase their bioactivity and osteointegration capacity.

For instance, we proved the relevance of the cold spray technique. Using such reactive apatites is not only a way to boost the biointegration of the implant and allow faster bone repair, but it also allows associating bioactive ions and molecular species, such as antimicrobials to fight or avoid infections. This approach is notably followed in the starting AIMed EU H2020 programme. (4)

Yes indeed. Biomimetic apatites have been developed initially with the idea to propose more efficient bioactive bone substitute materials capable of being functionalised to provide additional effects in vivo, which we showed has great promise. But taking into account their intrinsic biocompatibility, it is also possible to extend the initial usages to a wealth of other medical applications!

In oncology, haematology, dermatology in all such domains where nanomedicine devices are needed, providing small systems to act at the level of cells. (5) It should probably be reminded that nanosized crystals are already present in our bodies since bone is a natural nanocomposite! Here, by designing bio-inspired apatites, we play with nanocrystals that our body can handle and whose biodegradation leads to natural metabolites.

We showed that it was possible to associate, to apatite nanoparticles, a cell targeting agent to address more specifically some diseased cells; that the bio-inspired apatite particle formulation could allow modifying the cellular uptake of some biomolecules/drugs; and that it was possible to design apatite systems for a smart delivery dependent on the body response.

This all opens new avenues of research, typically where an action is needed at a cellular or tissular level. Of course, this requires adapting the formulation and composition to the clinical application, which is why a close contact between materials scientists, galenic pharmacists, clinicians and industrials are needed.

But the role of politicians and decision-makers is also primordial to sustain these developments.

Well, the community now has a strong background on biomimetic/bio-inspired apatites, their elaboration, characterisation, behaviour, processing and properties to certify that these compounds are worth investing further research efforts! However, since the opportunities of use are wide and not yet fully explored by far, additional work is needed in several strategic domains to further ascertain and determine the power of bio-inspired apatites, including in comparison to existing devices often less biocompatible.

Decision-makers could help to promote an active development of biomimetic apatite-based systems by 1) launching dedicated calls for projects at national and European/international scales and providing the necessary funds, 2) setting up a committee of experts about bio-inspired apatites for coordinating research actions, 3) facilitating the development of standards dedicated to such metastable compounds.

In my opinion, this all could allow progressing significantly toward the validation and use of highly-bioactive apatite-based systems in tomorrows medicine for the good of our patientsand the whole healthcare system since these systems are rather low-cost to produce.

(1) Drouet, C. et al. 2018. Nanocrystalline apatites: The fundamental role of water. Am. Miner. 103;550-564.

(2) Grossin, D. et al. 2010. Biomimetic apatite sintered at very low temperature by spark plasma sintering: Physico-chemistry and microstructure aspects. Acta Biomat. 6;577-585.

(3) Luginina et al., First successful stabilization of consolidated amorphous calcium phosphate (ACP) by cold sintering: toward highly-resorbable reactive bioceramics J. Mat. Chem. B, 8 (2020) 629-635.

(4) Horizon 2020 research and innovation programme, Marie Skodowska-Curie grant agreement No 861138,

(5) Drouet, C. et al. 2020. Colloidal apatite particles: a multifunctional platform in (nano)medicine. Juniper Online J. Mater. Sci. 6 (1);art.555676;1-8.

Member (and PhD supervisor) of the H2020 project AIMed.

*Please note: This is a commercial profile

Editor's Recommended Articles

Continued here:
The advent of biomimetic apatites in today's and tomorrow's medicine - Open Access Government

Posted in Nano Medicine | Comments Off on The advent of biomimetic apatites in today’s and tomorrow’s medicine – Open Access Government

Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish – Stanford University News

by Crista Leigh Farrell on December 4, 2020 4:24 pm

JOSEPH DESIMONE, the Sanjiv Sam Gambhir Professor in Translational Medicine and professor of chemical engineering, has been named the recipient of the 2019-20 Harvey Prize in science and technology in recognition of contributions in materials science, chemistry, polymer science and technology, nanomedicine, and 3D printing.

Joseph DeSimone

The Harvey Prize, the highest honor of the Technion-Israel Institute of Technology, recognizes breakthroughs in research that benefit humanity. The prize administrators said DeSimones work is a model for combining basic scientific discoveries with developments of industrial technologies that have a significant influence.

It is incredibly humbling to be selected for the Harvey Prize, said DeSimone. I have been fortunate in my career to work with brilliant students and colleagues to make advances in science and technology toward improving the human condition, and this is a tremendous honor and testament to our work together.

DeSimone, who joined the Stanford faculty in September, holds faculty appointments in the Department of Radiology, the Department of Chemical Engineering and, by courtesy, the Graduate School of Business. He previously held a joint appointment in chemistry and chemical engineering at the University of North Carolina at Chapel Hill and North Carolina State University.

An author of more than 350 scientific articles and an inventor on more than 200 issued patents, DeSimone is known for advances rooted in polymer science that have spawned new technologies and areas of research, as well as for translating discoveries made in his laboratory to the marketplace.

In the 1990s, he and students invented an environmentally friendly process for synthesizing high-performance plastics without the use of hazardous solvents. In 2004, DeSimone and his team invented a breakthrough nanoparticle fabrication process, leading to the launch of multiple medical products in clinical trials. In 2015, he and colleagues reported a breakthrough advance in polymer 3D printing, which led DeSimone to co-found Carbon, a company whose technology has enabled cutting-edge products in such industries as footwear, dental, medical, automotive and aerospace.

DeSimone is one of only 25 people elected to all three branches of the U.S. national academies (Sciences, Engineering and Medicine). In 2016, President Obama presented him with the National Medal of Technology and Innovation.

DeSimone joins other Stanford faculty members as a winner of the Harvey Prize, including RICHARD ZARE, DONALD KNUTH, ROGER KORNBERG, KARL DEISSEROTH and CARLA SHATZ.

DeSimone will receive the prize at the Technion in Haifa, Israel, in June if pandemic conditions permit.

Go here to read the rest:
Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish - Stanford University News

Posted in Nano Medicine | Comments Off on Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish – Stanford University News

Nordic Nanovector ASA: Results for the Third Quarter 2020 – BioSpace

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the presentation is available from the company's homepage (

Lars Nieba, Interim CEO of Nordic Nanovector, said: "Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Generating these data will require us to successfully navigate the latest challenges of increased COVID-19 restrictions. We remain confident in our ability to achieve this goal, aided by the protocol amendments, the possibility to reduce the patient sample, and all the other measures we are actively implementing to drive patient recruitment into PARADIGME."

Q3'2020 Highlights

Events after Q3'2020

Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)


The company continues to target the readout of three-month top line data from PARADIGME in H2'2021. Approval of protocol amendments is proceeding as planned and completed in the best-recruiting countries, and other initiatives to increase the rate of enrolment are underway. The company also targets the readout of three-month top line data from the second cohort of the Archer-1 trial in H1'2021.

However, the impact of the COVID-19 pandemic on patient recruitment has worsened in light of the emergence of a second wave resulting in severe travel restrictions being implemented in the various countries where we are executing our clinical studies. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Several proactive actions have been taken to minimize the impact of these travel restrictions which could blunt further delays in completing enrolment and delivering preliminary results as targeted.

The company has taken steps to conserve cash and following the recent successful private placement, Nordic Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has made in the last nine months have improved the prospects of delivering pivotal results from PARADIGME in H2'2021.

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients.

Presentation and live webcast Q3 2020 results

A presentation and live webcast by Nordic Nanovector's management team will take place today at 8:30 am CET.

The webcast can be accessed from in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation is available at in the section: Investors & Media/Reports and Presentation/Interim Reports/2020.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762


Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535


About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Further information can be found at .

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision,c3239830

The following files are available for download:

View original content:

SOURCE Nordic Nanovector

Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL

Visit link:
Nordic Nanovector ASA: Results for the Third Quarter 2020 - BioSpace

Posted in Nano Medicine | Comments Off on Nordic Nanovector ASA: Results for the Third Quarter 2020 – BioSpace

Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) – TechnoWeekly

The global Healthcare Nanotechnology (Nanomedicine) Market study offers a compilation of the current, historical, and future outlook of the industry as well as the factors responsible for market growth. With a SWOT analysis, the business study highlights the weaknesses, strengths, opportunities, and threats of each Healthcare Nanotechnology (Nanomedicine) Market player in a comprehensive way.

Sample Copy of This Report:

Under the COVID-19 outbreak analysis, this report provides analysis of import, supply chain, and export to future influence on the industry and regional government policies. Enterprise competition pattern, detailed analysis about market status, advantages and disadvantages of enterprise products, macroeconomic policies and regional industrial layout characteristics, industry development trends have also been included. The trends of product sales channel will be offered as well.

Considering COVID-19, this report offers a complete and exhaustive analysis on how the epidemic has pushed transformation and reform in the industry. The market study can help understand the market expansion and strategies for business accordingly. In the strategy analysis, it gives insights from market positioning marketing channel to potential growth strategies, thereby providing an in-depth analysis for new entrants or existing competitors in the Healthcare Nanotechnology (Nanomedicine) industry.

Key Players: Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd..

The market analysis on the Healthcare Nanotechnology (Nanomedicine) offers a birds eye view of the current proceeding within the Healthcare Nanotechnology (Nanomedicine) Market. The market analysis report has incorporated an analysis of various factors that augment the markets growth. It constitutes restraints, trends, and drivers that transform the market in either a negative orpositive manner.

Healthcare Nanotechnology (Nanomedicine) Market

Get ToC for the overview of the premium report @

This market analysis also offers the scope of different segments and applications that can actually impact the market in the future. The thorough information is based on present trends and historic milestones. The market analysis mentions the volume of sales by region from 2015 to 2026. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives room for strategic planning.

Global Healthcare Nanotechnology (Nanomedicine) Market: Segment Analysis

Each type offers information about return sover the forecast period of 2018 to 2028. The sales method segment also offers revenue by volume and sales over the forecast period of 2018 to 2028. Understanding the segments helps in classifying the importance of various factors that support market growth.

Following are the segmentation covered by the market study: By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Global Healthcare Nanotechnology (Nanomedicine) Market: Regional Analysis

The market analysis report includes a thorough study of various factors that determine regional growth such as environmental, economic, social political status, technology, and region. Market analysis has studied the data of sales, revenue, and manufacturers of each region. The market analysis provides region-wise volume and revenue for the forecast period of 2016 to 2028. This market analysis will support the market participants to understand the potential worth of investment in a particular region.

Region- wise Analysis of the Global Healthcare Nanotechnology (Nanomedicine) Market covers: North America Europe Asia Pacific Middle East and Africa South America

Make an Enquiry for purchasing this Report @

Global Healthcare Nanotechnology (Nanomedicine) Market: Competitive Landscape

This market analysis report classifies numerous key manufacturers of the industry. It supports the reader in understanding the policies and collaborations that the industry participants are focusing on in order to combat competition in the industry. The comprehensive market analysis offers a note worthy microscopic look at the industry. The market analysis can classify the footprints of the manufacturers by giving the global revenue of manufacturers and sales by manufacturers, and the global price of manufacturers over the forecast period of 2018 to 2028.

Major Aspects covered in the Report are

Further, the report provides niche insights for a decision about every possible segment, helping in the strategic decision-making process and market size estimation of the Healthcare Nanotechnology (Nanomedicine) Market on a regional and global basis. Unique research designed for market size estimation and forecast is used for the identification of major companies operating in the market with related developments. The report has an exhaustive scope to cover all the possible segments, helping every stakeholder in the Healthcare Nanotechnology (Nanomedicine) Market.

Reasons for buying this report:

Why Do Companies Trust QMI?


QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.


Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]


Excerpt from:
Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) - TechnoWeekly

Posted in Nano Medicine | Comments Off on Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) – TechnoWeekly

NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States – Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the SEC) relating to a proposed initial public offering of its American Depositary Shares (ADSs), representing ordinary shares, in the United States (the U.S. Offering), and a concurrent private placement of its ordinary shares in Europe (including France) and other countries outside of the United States (the European Private Placement, and together with the U.S. Offering, the Global Offering). All securities to be sold in the Global Offering will be offered by the Company. The number of ordinary shares to be represented by each ADS, the number of ADSs and ordinary shares to be offered and the price range for the proposed Global Offering have not yet been determined. The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol NBTX. The Companys ordinary shares are listed on Euronext Paris under the symbol NANO.

Jefferies LLC is acting as global coordinator for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are also acting as joint book-running managers for the U.S. Offering. Gilbert Dupont is acting as manager for the European Private Placement.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at

A registration statement relating to the securities referred to herein has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The registration statement can be accessed by the public on the website of the SEC.


Nanobiotix is a French, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. Nanobiotixs novel, proprietary lead technology, NBTXR3, is being evaluated in locally-advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Nanobiotix is also running an Immuno-Oncology development program. The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, Massachusetts, and European affiliates in France, Spain and Germany.

Read more here:
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States - Business Wire

Posted in Nano Medicine | Comments Off on NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States – Business Wire